AstraZeneca PLC (NASDAQ: AZN) is a multinational pharmaceutical and biotechnology company headquartered in Cambridge, United Kingdom. The company focuses on the discovery, development, and commercialization of prescription medicines in various therapeutic areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. AstraZeneca operates in over 100 countries worldwide.
Key Takeaways:
- AstraZeneca’s strong pipeline and strategic acquisitions position the company for sustained growth.
- The company’s focus on oncology, cardiovascular, renal, metabolism, and respiratory diseases aligns with global health trends.
- AstraZeneca’s stock price is projected to experience significant appreciation over the coming decades.
Overview of AstraZeneca
AstraZeneca is a multinational pharmaceutical and biotechnology company headquartered in Cambridge, England. Founded in 1999 through the merger of Astra AB and Zeneca Group.
AstraZeneca is at the forefront of pharmaceutical innovation, with a diverse portfolio of groundbreaking medicines. The company has made significant strides in oncology with Tagrisso, revolutionized diabetes and heart failure treatment with Farxiga, and effectively managed high cholesterol with Crestor, solidifying its position as a leader in 21st-century healthcare.
AstraZeneca Company Profile
| Country | United Kingdom |
| Ticker Symbol | AZN |
| Exchange | NASDAQ |
| Founded | 1999 |
| IPO Date | 1993 |
| Industry | Drug Manufacturers – General |
| Sector | Healthcare |
| Employees | 89,900 |
| CEO | Pascal Soriot |
| Market Cap (May 28, 2024) | $237.55 billion |
| Website | astrazeneca |
AstraZeneca (AZN) Balance Sheet Analysis
AstraZeneca PLC (NASDAQ: AZN) reported a strong balance sheet for the fiscal year ended December 31, 2023. Total assets reached $101.1 billion, up 4.8% from 2022. Liabilities, net of minority interest, amounted to $62.0 billion.
Equity, gross of minority interest, stood at $39.2 billion, a 5.7% increase. Total capitalization reached $61.5 billion, with common stock equity increasing to $39.1 billion.
Capital lease obligations grew to $1.1 billion. Net tangible assets and working capital remained negative at $19.0 billion and $5.5 billion, respectively. Invested capital increased to $66.6 billion.
Total debt slightly decreased to $28.6 billion, while net debt decreased to $21.7 billion. Ordinary shares issued increased to 1,550,162,630, with no preferred shares reported.
Balance Sheet Data Source: finance.yahoo
AstraZeneca Stock Price History
AstraZeneca (AZN) has undergone two stock splits since its IPO in 1993. The first split occurred on April 8th, 1998, with a 3:1 split, tripling the number of outstanding shares.
The most recent split took place on July 27th, 2015, with a 2:1 split, further doubling the shares. As a result, one AZN share purchased before the 1998 split would now equal six shares.1
As of May 28, the stock stands at $76.62.
AstraZeneca Stock Price Forecast 2024
For 2024, we project AstraZeneca’s stock price to experience modest growth, with an average price target of $85.47. This represents an 11.56% increase from the current price of $76.62 as of May 28, 2024. AstraZeneca’s growth in 2024 will be driven by its robust pipeline, which includes promising candidates in oncology, such as Enhertu and Imfinzi, as well as the company’s continued expansion in emerging markets.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2024 | $60.45 | $85.47 | $90.49 |
AstraZeneca Stock Price Forecast 2025
Looking ahead to 2025, we anticipate AstraZeneca’s stock price to continue its upward momentum, supported by the company’s robust pipeline and strategic initiatives. Our analysis suggests an average price target of $95.70, indicating an 11.95% increase from the 2024 average price. In 2025, AstraZeneca is expected to benefit from the growing demand for its diabetes and cardiovascular treatments, such as Farxiga and Brilinta, as well as the potential approval and launch of new drugs in its pipeline.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2025 | $90.11 | $95.70 | $101.29 |
AstraZeneca Stock Price Forecast 2026
In 2026, AstraZeneca’s stock price is expected to surpass the $100 mark, driven by the company’s expanding presence in key therapeutic areas and its ability to capitalize on market opportunities. We forecast an average price target of $107.18, representing a 12.00% increase from the 2025 average price. AstraZeneca’s growth in 2026 will be supported by the continued success of its oncology portfolio, the increasing adoption of its respiratory treatments, and the potential for strategic acquisitions and partnerships.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2026 | $100.92 | $107.18 | $113.44 |
AstraZeneca Stock Price Forecast 2027
As AstraZeneca continues to innovate and enhance its product offerings, we anticipate the company’s stock price to maintain its growth trajectory in 2027. Our analysis indicates an average price target of $120.03, reflecting a 12.00% increase from the 2026 average price. In 2027, AstraZeneca is expected to benefit from the growing demand for personalized medicine and the potential for groundbreaking advancements in its research and development efforts.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2027 | $113.03 | $120.03 | $127.04 |
AstraZeneca Stock Price Forecast 2028
By 2028, AstraZeneca’s stock price is projected to reach new heights, supported by the company’s strong financial performance and market position. We forecast an average price target of $134.44, representing a 12.00% increase from the 2027 average price. AstraZeneca’s growth in 2028 will be driven by the continued expansion of its global presence, the potential for new drug approvals and launches, and the company’s ability to adapt to evolving healthcare needs.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2028 | $126.59 | $134.44 | $142.28 |
AstraZeneca Stock Price Forecast 2029
In 2029, we expect AstraZeneca’s stock price to continue its upward trend, driven by the company’s ability to deliver innovative treatments and capitalize on global health trends. Our analysis suggests an average price target of $150.57, indicating a 12.00% increase from the 2028 average price. AstraZeneca’s growth in 2029 will be supported by the increasing demand for its products in emerging markets, the potential for strategic partnerships and collaborations, and the company’s ongoing commitment to research and development.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2029 | $141.79 | $150.57 | $159.35 |
AstraZeneca Stock Price Forecast 2030
As AstraZeneca enters the new decade, we anticipate the company’s stock price to maintain its growth momentum. Our forecast for 2030 indicates an average price target of $168.64, representing a 12.00% increase from the 2029 average price. In 2030, AstraZeneca is expected to benefit from the growing demand for preventive healthcare solutions, the potential for breakthrough discoveries in its research pipeline, and the company’s ability to leverage digital technologies to enhance its operations and patient care.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2030 | $158.80 | $168.64 | $178.48 |
Related: Thermo Fisher Scientific (TMO) Stock Forecast & Price Prediction
AstraZeneca Stock Price Forecast 2031
In 2031, AstraZeneca’s stock price is projected to continue its ascent, supported by the company’s robust pipeline and strategic partnerships. We forecast an average price target of $188.87, reflecting a 12.00% increase from the 2030 average price. AstraZeneca’s growth in 2031 will be driven by the increasing prevalence of chronic diseases, the potential for new drug approvals and launches, and the company’s ability to capitalize on the growing demand for personalized medicine.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2031 | $177.86 | $188.87 | $199.89 |
AstraZeneca Stock Price Forecast 2032
By 2032, AstraZeneca’s stock price is expected to surpass the $200 mark, driven by the company’s sustained growth and market leadership. Our analysis indicates an average price target of $211.54, representing a 12.00% increase from the 2031 average price. In 2032, AstraZeneca is expected to benefit from the growing demand for innovative cancer treatments, the potential for strategic acquisitions and partnerships, and the company’s ongoing commitment to research and development in key therapeutic areas.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2032 | $199.21 | $211.54 | $223.88 |
AstraZeneca Stock Price Forecast 2033
In 2033, we anticipate AstraZeneca’s stock price to maintain its upward trajectory, supported by the company’s strong financial performance and ability to adapt to evolving market dynamics. Our forecast suggests an average price target of $236.92, indicating a 12.00% increase from the 2032 average price. AstraZeneca’s growth in 2033 will be driven by the increasing demand for its respiratory and immunology treatments, the potential for groundbreaking advancements in its research pipeline, and the company’s ability to leverage digital technologies to enhance its operations and patient care.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2033 | $223.11 | $236.92 | $250.74 |
AstraZeneca Stock Price Forecast 2034
As AstraZeneca continues to innovate and expand its global presence, we expect the company’s stock price to experience sustained growth in 2034. Our analysis projects an average price target of $265.35, representing a 12.00% increase from the 2033 average price. In 2034, AstraZeneca is expected to benefit from the growing demand for its cardiovascular and metabolic treatments, the potential for new drug approvals and launches, and the company’s ongoing commitment to research and development in emerging therapeutic areas.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2034 | $249.89 | $265.35 | $280.82 |
AstraZeneca Stock Price Forecast 2035
In 2035, AstraZeneca’s stock price is expected to maintain its upward momentum, driven by the company’s robust pipeline and ability to capitalize on emerging market opportunities. We forecast an average price target of $297.19, reflecting a 12.00% increase from the 2034 average price. AstraZeneca’s growth in 2035 will be supported by the increasing demand for personalized medicine, the potential for strategic partnerships and collaborations, and the company’s ongoing commitment to research and development in key therapeutic areas.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2035 | $279.87 | $297.19 | $314.52 |
AstraZeneca Stock Price Forecast 2036
By 2036, AstraZeneca’s stock price is projected to surpass the $300 mark, supported by the company’s strong market position and ability to deliver innovative treatments. Our analysis suggests an average price target of $332.86, indicating a 12.00% increase from the 2035 average price. In 2036, AstraZeneca is expected to benefit from the growing demand for its oncology and respiratory treatments, the potential for groundbreaking advancements in its research pipeline, and the company’s ability to leverage digital technologies to enhance its operations and patient care.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2036 | $313.46 | $332.86 | $352.26 |
AstraZeneca Stock Price Forecast 2037
In 2037, we anticipate AstraZeneca’s stock price to continue its ascent, driven by the company’s sustained growth and ability to adapt to evolving healthcare needs. Our forecast indicates an average price target of $372.80, representing a 12.00% increase from the 2036 average price. AstraZeneca’s growth in 2037 will be supported by the increasing prevalence of chronic diseases, the potential for new drug approvals and launches, and the company’s ongoing commitment to research and development in emerging therapeutic areas.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2037 | $351.07 | $372.80 | $394.53 |
AstraZeneca Stock Price Forecast 2038
As AstraZeneca approaches the end of the decade, we expect the company’s stock price to maintain its growth trajectory, supported by its strong fundamentals and market leadership. Our analysis projects an average price target of $417.54, reflecting a 12.00% increase from the 2037 average price. In 2038, AstraZeneca is expected to benefit from the growing demand for personalized medicine, the potential for strategic partnerships and collaborations, and the company’s ongoing commitment to research and development in key therapeutic areas.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2038 | $393.20 | $417.54 | $441.88 |
AstraZeneca Stock Price Forecast 2039
In 2039, AstraZeneca’s stock price is expected to continue its upward trend, driven by the company’s ability to innovate and capitalize on global health trends. We forecast an average price target of $467.64, indicating a 12.00% increase from the 2038 average price. AstraZeneca’s growth in 2039 will be supported by the increasing demand for its cardiovascular and metabolic treatments, the potential for groundbreaking advancements in its research pipeline, and the company’s ability to leverage digital technologies to enhance its operations and patient care.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2039 | $440.39 | $467.64 | $494.90 |
AstraZeneca Stock Price Forecast 2040
As AstraZeneca enters the new decade, we anticipate the company’s stock price to maintain its growth momentum, supported by its robust pipeline and strategic partnerships. Our analysis suggests an average price target of $523.76, representing a 12.00% increase from the 2039 average price. In 2040, AstraZeneca is expected to benefit from the growing demand for innovative cancer treatments, the potential for new drug approvals and launches, and the company’s ongoing commitment to research and development in emerging therapeutic areas.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2040 | $493.23 | $523.76 | $554.29 |
AstraZeneca Stock Price Forecast 2050
Looking ahead to 2050, we project AstraZeneca’s stock price to reach new heights, driven by the company’s sustained growth, market leadership, and ability to adapt to evolving healthcare needs. Our forecast indicates an average price target of $1,400.00, reflecting a 167.34% increase from the 2040 average price. This represents a compound annual growth rate (CAGR) of 10.33% from 2024 to 2050. AstraZeneca’s growth in 2050 will be supported by the company’s ongoing commitment to innovation, its ability to capitalize on emerging market opportunities, and its leadership in key therapeutic areas such as oncology, cardiovascular, and respiratory diseases.
| Year | Low Price | Average Price | High Price |
|---|---|---|---|
| 2050 | $1,260.00 | $1,400.00 | $1,540.00 |
Conclusion
Our comprehensive analysis of AstraZeneca’s stock price forecast from 2024 to 2050 highlights the company’s potential for sustained growth and value creation. With a strong pipeline, strategic partnerships, and a focus on key therapeutic areas, AstraZeneca is well-positioned to capitalize on global health trends and deliver innovative treatments to patients worldwide. For investors seeking long-term growth opportunities, AstraZeneca presents an attractive option, with its stock price projected to appreciate significantly over the coming decades.
FAQs
1. Is it a good time to buy AstraZeneca shares?
Based on our long-term stock price forecast, AstraZeneca appears to be a promising investment opportunity for those seeking growth and value. The company’s strong pipeline, strategic partnerships, and focus on key therapeutic areas position it well for sustained growth.
2. Who owns the most shares in AstraZeneca?
As of the most recent available data, the largest shareholder of AstraZeneca is BlackRock, Inc., a multinational investment management corporation based in the United States. BlackRock holds a significant stake in the company through its various funds and investment vehicles.
3. Why is AstraZeneca a good company?
AstraZeneca is considered a good company for several reasons:
(a) . Strong pipeline: AstraZeneca has a robust pipeline of innovative medicines across various therapeutic areas, positioning the company for future growth.
(b) . Focus on key therapeutic areas: The company’s focus on oncology, cardiovascular, renal, metabolism, and respiratory diseases aligns with global health trends and unmet medical needs.
(c) . Strategic partnerships: AstraZeneca has established strategic partnerships and collaborations with other leading pharmaceutical companies, academic institutions, and research organizations to advance its research and development efforts.
(d) . Global presence: With operations in over 100 countries, AstraZeneca has a strong global presence and is well-positioned to capitalize on emerging market opportunities.
(e) . Financial performance: AstraZeneca has demonstrated consistent financial performance, with a track record of revenue growth and profitability.
4. Who is AstraZeneca’s biggest competitor?
AstraZeneca faces competition from several large pharmaceutical companies, depending on the specific therapeutic area. Some of its key competitors include: a. Pfizer Inc. b. Merck & Co., Inc. c. Bristol-Myers Squibb Company d. Roche Holding AG e. GlaxoSmithKline plc f. Novartis AG These companies compete with AstraZeneca in various therapeutic areas, such as oncology, cardiovascular, and respiratory diseases.
5. Who are the largest shareholders of AstraZeneca?
According to recent data, some of the largest shareholders of AstraZeneca include: a. BlackRock, Inc. b. Vanguard Group, Inc. c. Wellington Management Group LLP d. Capital Research and Management Company e. State Street Corporation f. Invesco Ltd. g. Norges Bank Investment Management These institutional investors hold significant stakes in AstraZeneca through their various funds and investment vehicles, reflecting confidence in the company’s long-term growth prospects.
Disclaimer:
The stock price predictions provided herein are based on historical data, current market trends, and analysis. However, past performance does not guarantee future results. Stock markets are inherently volatile and subject to numerous economic, political, and market factors that can cause rapid and unpredictable fluctuations in stock prices. The information provided is for educational and informational purposes only and should not be construed as financial advice. It is strongly recommended that you consult with a qualified financial advisor before making any investment decisions. Invest responsibly and consider your individual financial situation, risk tolerance, and investment objectives before acting on any information provided.
Source:
